Wedbush analyst Zarak Khurshid weighed in on Exact Sciences (NASDAQ: EXAS) following the USPSTF draft recommendation which was not as ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Exact Sciences (EXAS) Drops Another 20%October 8, 2015 11:25 AM Whitney Tilson Says Exact Sciences (EXAS) Still a Great ShortOctober 7, 2015 10:20 AM Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines October 7, 2015 6:50 AM Lake Street Capital Markets Downgrades Exact Sciences (EXAS) to HoldOctober 6, 2015 1:44 PM Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on WeaknessOctober 6, 2015 12:14 PM Exact Sciences (EXAS) PT Slashed to $11 at Goldman Sachs on Negative USPSTF RulingOctober 6, 2015 9:32 AM Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines October 6, 2015 8:45 AM Benchmark Downgrades Exact Sciences (EXAS) to HoldOctober 6, 2015 8:03 AM Impact on Exact Sciences (EXAS) from USPSTF Guidlines 'Unclear', Jefferies Says; Would Be Buyers on WeaknessOctober 6, 2015 6:53 AM Exact Sciences (EXAS) Issues Statement on USPSTF Colorectal Cancer Screening Draft RecommendationOctober 6, 2015 6:29 AM Cologuard® Included as Alternative Screening Test under Draft USPSTF GuidelinesOctober 5, 2015 8:21 PM Exact Sciences (EXAS) Shares Drop After-HoursOctober 5, 2015 5:45 PM